Imatinib (a BCR-ABL tyrosine kinase inhibitor), trastuzumab (a monoclonal antibody directed against HER2), or PD-1/PD-L1 inhibitors are examples of therapies that have revolutionized the treatment of patients with various types of cancers [23]. Here, ERBB2 is linked to cancer.